Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 24 |
| Active Pipeline (Recruiting Now) | 12 (8) |
| Completed vs Stopped Early | 7 / 2 (8.3%) |
| Median Closed Actual Enrollment | 45 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| St. Michael's Hospital | Toronto, Ontario | 3 |
| CancerCare Manitoba | Winnipeg, Manitoba | 2 |
| University of Chicago Medicine | Chicago, IL | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05848713 | AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia | Phase III | RECRUITING |
| NCT03378466 | Heparin Anticoagulation in Septic Shock | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the University of Manitoba Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.